President & CEO
Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He joined Artiva Biotherapeutics as CEO in January of 2021 and led the company’s Series B financing and IPO, and transition from preclinical to clinical-stage with research and GMP manufacturing capabilities.
Prior to Artiva, Fred was President and CBO at Vividion Therapeutics (acquired by Bayer). Prior to Vividion, Fred had a 12-year affiliation with Venrock. From 2006 to 2013, he was part of Venrock’s healthcare investment team, where he had the opportunity to co-found and serve as a board member of Receptos Pharmaceuticals. Subsequently, from 2011 to 2018, he was CEO of Adavium Medical, a medical device company he founded, with Venrock as its largest investor. Fred’s prior roles include director of business development and head of investor relations for CuraGen and consultant at Boston Consulting Group. Fred holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine and an MBA from Harvard Business School.